Investment Highlights for NeXtGen™ Biologics Inc.

NeXtGen™ Biologics Inc.
13800 Tech City Cir, #200
Alachua, FL 32615
Phone: (800) 209-7190
https://www.nextgenbiologics.com/

• NeXtGen Biologics’ extracellular matrix (ECM) technology is unique in all aspects of the surgical markets. The Company’s first product, NeoMatriX® Wound Matrix, is the foundation of this platform technology. The product uses the dermis of the axolotl, an animal that has been long studied regarding its inherent regenerative nature.
  
  
• The neotenic characteristics of axolotls, combined with their remarkable regenerative abilities, make them valuable subjects for scientific research with potential applications in regenerative medicine, including wound healing. By studying these fascinating amphibians, scientists hope to unlock new insights into tissue regeneration and develop innovative therapies to improve human health.
  
  
• NeoMatriX was first FDA cleared as a 510(k) medical device in 2018 and again for in-house process in 2021. The Company’s proprietary manufacturing process removes elements that may otherwise cause a reaction in a patient after application, while retaining native structural ECM constituents. Currently, NeoMatriX is available in sterile sheets of various sizes for wound bed placement. Clinical use demonstrates promising results when used by physicians for patients suffering from chronic and difficult to heal wounds.
  
  
• Every year, approximately 12 million U.S. patients suffer traumatic lacerations that are treated in the emergency room and 250 million people worldwide undergo surgical incisions. Chronic wounds affect 6.5 million people in the U.S. In many cases, these wounds carry the risk of scar formation, adhesions, incomplete remodeling, and infection.
  
  
• Despite significant technological advancements, the management of surgical and chronic wounds remains a challenge. There is no solution available to date that guarantees scar-free healing. Also, surgically treated conditions may lead to complications, such as non-closure, dehiscence, and recurrence, causing distress for patients and imposing substantial financial burdens on payors.
  
  
• NeXtGen’s product offers unique competitive advantages, including that it can be stored at room temperature (off the shelf); is sterile, where no viruses will be transmissible to humans; is naturally adherent, versatile and durable; provides for easy placement, where it can be used for partial and full-thickness wounds; offers on-demand manufacturing; and has scalable technology that is cost competitive. 
  
  
• NeXtGen is prepared to launch what it considers a genuinely “next generation” platform for wound care and associated technologies into the estimated $13.67 billion 2025 North American target market. This endeavor takes place within the broader context of the estimated $66 billion worldwide regenerative medicine market of 2022, which is recognized as the fastest-growing sector in medical devices, as indicated by recent merger and acquisition transactions and IPO activities.
  
  
• The Company has received $16.2 million of funding to date, including a $1.3 million SEED round (closed); $7.9 million raised through convertible notes (8% interest and 20% discount in “qualified equity financing”); and $6.4 million Common Stock (with $0.5mm remaining to reach convertible note). It currently seeks to raise an additional $5 million.
  
  
• NeXtGen is led by a highly experienced management team and Board of Directors with proven success in pharmaceutical research, development, and commercialization. Jonelle Toothman, Co-founder & CEO, has 15+ years of experience in leadership roles commercializing medical device products and positioning companies for acquisition and has been part owner of several ventures; and Jamie Grooms, Co-founder & Chairman of the Board, has been Co-founder and former CEO of 2 startup regenerative companies (RTI Surgical [NASDAQ: RTIX], and AxoGen, Inc. [NASDAQ: AXGN]).
  
  
• NeXtGen exclusively owns a portfolio of Trade Secrets and U.S. and foreign issued and pending patent rights for medical devices, implants, coatings, cosmetics, biologicals, pharmacological, and other therapeutic technologies.